UK Casts Wider Net With Pfizer/BioNTech’s COVID-19 Vaccine
Longer Time Lag Between Two Doses Will Maximize Vaccination Outreach
The UK MHRA has crunched the safety and effectiveness data on the Pfizer/BioNTech COVID-19 vaccine and permitted its use by even more people.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
The European Medicines Agency may issue an opinion on approving AstraZeneca’s COVID-19 vaccine by 29 January if the data are robust and complete and any additional data requests are dealt with promptly.
UK regulator admits evidence sparse on older patients, but believes longer gap between doses can boost efficacy and accelerate numbers of people immunized.